Inventor · disambiguated record
Adrian Bot
Also filed as: BOT ADRIAN · BOT ADRIAN I · BOT ADRIAN IAN · BOT ADRIAN ION
22 granted patents·40 pending applications·417 citations·filing 1996–2025
96Inventor score
Top patents by PatentIndex Score
62 records- 0195US10322146B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2017·Granted Jun 18, 2019·17 cites·30 claims
- 0295US9855298B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2016·Granted Jan 2, 2018·80 cites·30 claims
- 0394US7511119B2PRAME peptide analoguesMANNKIND CORP·Filed 2006·Granted Mar 31, 2009·12 cites·26 claims
- 0493US8354380B2NY-ESO-1 peptide analogsMANNKIND CORP·Filed 2005·Granted Jan 15, 2013·18 cites·45 claims
- 0593US6630169B1Particulate delivery systems and methods of useNEKTAR THERAPEUTICS·Filed 1999·Granted Oct 7, 2003·163 cites·52 claims
- 0691US8653237B2Peptide analoguesLIU LIPING·Filed 2012·Granted Feb 18, 2014·13 cites·13 claims
- 0791US7511118B2PSMA peptide analoguesMANNKIND CORP·Filed 2006·Granted Mar 31, 2009·11 cites·33 claims
- 0890US8703142B2Methods to bypass CD4+ cells in the induction of an immune responseDIAMOND DAVID C·Filed 2005·Granted Apr 22, 2014·17 cites·45 claims
- 0989US11779601B2Diagnostic methods for T cell therapyKITE PHARMA INC·Filed 2016·Granted Oct 10, 2023·5 cites·13 claims
- 1088US7605227B2Melanoma antigen peptide analoguesMANNKIND CORP·Filed 2006·Granted Oct 20, 2009·9 cites·23 claims
- 1187US11491187B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2018·Granted Nov 8, 2022·2 cites·15 claims
- 1286US7999088B2Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stromaMANNKIND CORP·Filed 2006·Granted Aug 16, 2011·3 cites·72 claims
- 1385US2025367221A1Methods of conditioning patients for t cell therapyKITE PHARMA INC·Filed 2025·Application pending·0 cites
- 1482US8674081B2Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stromaQIU ZHIYONG·Filed 2011·Granted Mar 18, 2014·2 cites·25 claims
- 1582US2025243258A1Chimeric receptor t cell treatment using characteristics of the tumor microenvironmentKITE PHARMA INC·Filed 2024·Application pending·0 cites
- 1681US12458654B2Methods of conditioning patients for T cell therapyKITE PHARMA INC·Filed 2022·Granted Nov 4, 2025·0 cites·12 claims
- 1777US8084592B2Multivalent entrain-and-amplify immunotherapeutics for carcinomaBOT ADRIAN ION·Filed 2006·Granted Dec 27, 2011·10 cites·37 claims
- 1876US2010303842A1Peptide analoguesMANNKIND CORP·Filed 2009·Application pending·0 cites
- 1975US6204250B1Immunization of infantsMOUNT SINAI MEDICAL CT OF THE·Filed 1996·Granted Mar 20, 2001·48 cites·19 claims
- 2073US7141236B2Methods and compositions for delivering macromolecules to or via the respiratory tractNEKTAR THERAPEUTICS·Filed 2002·Granted Nov 28, 2006·5 cites·39 claims
- 2173US2022265721A1Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cellsKITE PHARMA INC·Filed 2022·Application pending·0 cites
- 2270US8809290B2Methods and compositions to generate and control the effector profile of T cells by simultaneous loading and activation of selected subsets of antigen presenting cellsBOT ADRIAN·Filed 2011·Granted Aug 19, 2014·2 cites·13 claims
- 2369US2009148478A1Combinations of tumor-associated antigens in compositions for various types of cancersMANNKIND CORP·Filed 2008·Application pending·0 cites
- 2468US12156887B2Chimeric receptor T cell treatment using characteristics of the tumor microenvironmentKITE PHARMA INC·Filed 2019·Granted Dec 3, 2024·0 cites·6 claims
- 2566US12480951B2Methods and compositions for T cell therapyKITE PHARMA INC·Filed 2022·Granted Nov 25, 2025·0 cites·15 claims
- 2666US11357796B2Treatment using chimeric receptor T cells incorporating optimized polyfunctional T cellsKITE PHARMA INC·Filed 2018·Granted Jun 14, 2022·0 cites·16 claims
- 2763US2007065369A1Novel methods and composition for delivering macromolecules to or via the respiratory tractBOT ADRIAN I·Filed 2006·Application pending·0 cites
- 2861US2005118186A1Combinations of tumor-associated antigens in compositions for various types of cancersFiled 2004·Application pending·0 cites
- 2958US12252701B2Chimeric antigen receptor T cell therapyKITE PHARMA INC·Filed 2021·Granted Mar 18, 2025·0 cites·16 claims
- 3058US2025144234A1RNA for In vivo Transfection with Increased ExpressionCAPSTAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3157US2023296610A1Predicting adverse events from immunotherapyKITE PHARMA INC·Filed 2023·Application pending·0 cites
- 3257US2009169571A1Selected ma motifs to include cell death and/or apoptosisMULTICELL IMMUNOTHERAPEUTICS I·Filed 2008·Application pending·0 cites
- 3355US2008199485A1Method for enhancing T cell responseMANNKIND CORP·Filed 2008·Application pending·0 cites
- 3455US2009131355A1Multicistronic vectors and methods for their designBOT ADRIAN ION·Filed 2008·Application pending·0 cites
- 3554US2004053871A1Immunization of infantsFiled 2003·Application pending·0 cites
- 3653US2011301327A1Epitope analogsLIU LIPING·Filed 2011·Application pending·0 cites
- 3753US2025313855A1Chimeric antigen receptor t cell therapyKITE PHARMA INC·Filed 2025·Application pending·0 cites
- 3853US2022387492A1Chimeric antigen receptor t cell therapyKITE PHARMA INC·Filed 2020·Application pending·0 cites
- 3952US2005074449A1Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the sameFiled 2004·Application pending·0 cites
- 4052US2002106368A1Novel methods and compositions to upregulate, redirect or limit immune responses to peptides, proteins and other bioactive compounds and vectors expressing the sameFiled 2001·Application pending·0 cites
- 4151US2005287068A1Efficacy of active immunotherapy by integrating diagnostic with therapeutic methodsBOT ADRIAN I·Filed 2005·Application pending·0 cites
- 4251US2006153844A1Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organsKUNDIG THOMAS·Filed 2005·Application pending·0 cites
- 4350US2022265719A1ImmunotherapiesKITE PHARMA INC·Filed 2022·Application pending·0 cites
- 4449US2022169694A1Chimeric antigen receptor t cell therapyKITE PHARMA INC·Filed 2021·Application pending·0 cites
- 4549US2020038442A1Chimeric antigen receptor therapy t cell expansion kinetics and uses thereofKITE PHARMA INC·Filed 2019·Application pending·0 cites
- 4649US2011230548A1Multicistronic vectors and methods for their designMANNKIND CORP·Filed 2011·Application pending·0 cites
- 4749US2006159689A1Combinations of tumor-associated antigens in diagnostics for various types of cancersCHIANG CHIH-SHENG·Filed 2005·Application pending·0 cites
- 4849US2006159694A1Combinations of tumor-associated antigens in compositions for various types of cancersCHIANG CHIH-SHENG·Filed 2005·Application pending·0 cites
- 4949US2006165711A1Methods to elicit, enhance and sustain immune responses against MHC class I-restricted epitopes, for prophylactic or therapeutic purposesBOT ADRIAN I·Filed 2005·Application pending·0 cites
- 5048US2006193855A1Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cellsBOT ADRIAN·Filed 2003·Application pending·0 cites
Showing the top 50 of 62 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Adrian Bot files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →